Bethge WA - Search Results

1

Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.

Bethge WA, Hegenbart U, Stuart MJ, Storer BE, Maris MB, Flowers ME, Maloney DG, Chauncey T, Bruno B, Agura E, Forman SJ, Blume KG, Niederwieser D, Storb R, Sandmaier BM. Bethge WA, et al. Blood. 2004 Feb 1;103(3):790-5. doi: 10.1182/blood-2003-07-2344. Epub 2003 Oct 2. Blood. 2004. PMID: 14525766 Free article. Clinical Trial.

2

Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts.

Sandmaier BM, Bethge WA, Wilbur DS, Hamlin DK, Santos EB, Brechbiel MW, Fisher DR, Storb R. Sandmaier BM, et al. Among authors: bethge wa. Blood. 2002 Jul 1;100(1):318-26. doi: 10.1182/blood-2001-12-0322. Blood. 2002. PMID: 12070043 Free article.

3

Selective T-cell ablation with bismuth-213-labeled anti-TCRalphabeta as nonmyeloablative conditioning for allogeneic canine marrow transplantation.

Bethge WA, Wilbur DS, Storb R, Hamlin DK, Santos EB, Brechbiel MW, Fisher DR, Sandmaier BM. Bethge WA, et al. Blood. 2003 Jun 15;101(12):5068-75. doi: 10.1182/blood-2002-12-3867. Epub 2003 Feb 27. Blood. 2003. PMID: 12609833 Free article.

4

Relapse or progression after hematopoietic cell transplantation using nonmyeloablative conditioning: effect of interventions on outcome.

Bethge WA, Storer BE, Maris MB, Flowers ME, Maloney DG, Chauncey TR, Woolfrey AE, Storb R, Sandmaier BM. Bethge WA, et al. Exp Hematol. 2003 Oct;31(10):974-80. doi: 10.1016/s0301-472x(03)00225-x. Exp Hematol. 2003. PMID: 14550814

5

Targeted cancer therapy and immunosuppression using radiolabeled monoclonal antibodies.

Bethge WA, Sandmaier BM. Bethge WA, et al. Semin Oncol. 2004 Feb;31(1):68-82. doi: 10.1053/j.seminoncol.2003.11.004. Semin Oncol. 2004. PMID: 14970939 Review.

6

Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: a dose deescalation study.

Bethge WA, Wilbur DS, Storb R, Hamlin DK, Santos EB, Brechbiel MW, Sandmaier BM. Bethge WA, et al. Transplantation. 2004 Aug 15;78(3):352-9. doi: 10.1097/01.tp.0000128853.62545.b2. Transplantation. 2004. PMID: 15316362

7

Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning.

Flowers ME, Traina F, Storer B, Maris M, Bethge WA, Carpenter P, Appelbaum F, Storb R, Sandmaier BM, Martin PJ. Flowers ME, et al. Among authors: bethge wa. Bone Marrow Transplant. 2005 Feb;35(3):277-82. doi: 10.1038/sj.bmt.1704767. Bone Marrow Transplant. 2005. PMID: 15558037

8

Targeted cancer therapy using radiolabeled monoclonal antibodies.

Bethge WA, Sandmaier BM. Bethge WA, et al. Technol Cancer Res Treat. 2005 Aug;4(4):393-405. doi: 10.1177/153303460500400407. Technol Cancer Res Treat. 2005. PMID: 16029058 Free article. Review.

9

Radioimmunotherapy as non-myeloablative conditioning for allogeneic marrow transplantation.

Bethge WA, Wilbur DS, Sandmaier BM. Bethge WA, et al. Leuk Lymphoma. 2006 Jul;47(7):1205-14. doi: 10.1080/00423110500485822. Leuk Lymphoma. 2006. PMID: 16923548 Review.

10

Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

Kahl C, Storer BE, Sandmaier BM, Mielcarek M, Maris MB, Blume KG, Niederwieser D, Chauncey TR, Forman SJ, Agura E, Leis JF, Bruno B, Langston A, Pulsipher MA, McSweeney PA, Wade JC, Epner E, Bo Petersen F, Bethge WA, Maloney DG, Storb R. Kahl C, et al. Among authors: bethge wa. Blood. 2007 Oct 1;110(7):2744-8. doi: 10.1182/blood-2007-03-078592. Epub 2007 Jun 26. Blood. 2007. PMID: 17595333 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

174 results

Search Page